
    
      A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to
      evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with
      primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH. The study consists of 3
      periods: (i) 4-week screening, (ii) 4-week randomized treatment, and (iii) 2-week follow up.
      The trial utilizes an operational design featuring the ability to conduct protocol required
      visits as either in clinic or remote visits (except Screening visit).
    
  